ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN 印刷: 0893-9675
ISSN オンライン: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v14.i1.40
pages 57-77

Role for the cAMP-Protein Kinase A Signaling Pathway in Suppression of Antitumor Immune Responses by Regulatory T Cells

Sheraz Yaqub
The Biotechnology Centre of Oslo and Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo; and Department of Gastroenterological Surgery, Akershus University Hospital, N-1478 Lørenskog, Norway
Kjetil Tasken
The Biotechnology Centre of Oslo and Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo, Norway

要約

CD4+CD25+ regulatory T (Treg) cells are engaged in the maintenance of immunological self-tolerance and suppressive control of excessive immune responses to foreign antigens. Furthermore, Treg cells infiltrate tumor tissues and may impede immune surveillance against cancer and hamper the development of an effective antitumor immunity. Depletion of Treg cells in animal models has been demonstrated to provoke tumor immunity. Attenuation of Treg-mediated suppression is therefore an interesting strategy to enhance antitumor responses. We recently found that adaptive Treg cells express COX-2 and suppress responder T cells in a PGE2-cAMP-dependent manner, which can be reversed by COX-2 inhibitors or EP-receptor antagonists. The same mechanism also appeared to be operative in patients with colorectal cancer where treatment with COX-inhibitor or cAMP-antagonist enhanced antitumor immune responses to the same extent as depletion of Treg cells. This provides mechanism-based opportunities for pharmacological intervention to interfere with Treg immunosuppression. In this review we will discuss key mechanisms used by Treg cells to suppress antitumor immunity, with emphasis on the cAMP-PKA pathway. We will also highlight some of the roles of Treg cells in cancer.


Articles with similar content:

IL-33 in Tumor Immunity: Nothing to Sneeze At
Critical Reviews™ in Immunology, Vol.38, 2018, issue 6
Bin Zhang, Donye Dominguez, Yi Zhang
Naturally Occurring Regulatory T Cells: Recent Insights in Health and Disease
Critical Reviews™ in Immunology, Vol.27, 2007, issue 1
Penelope A. Morel, Giorgio Raimondi, Michael S. Turner, Angus W. Thomson
Induction of RKIP Expression by Anticancer Therapeutic Antibodies and Its Role in the Reversal of Chemo- and Immunoresistance
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 2
Benjamin Bonavida
Understanding How Lipopolysaccharide Impacts CD4 T-Cell Immunity
Critical Reviews™ in Immunology, Vol.28, 2008, issue 4
Anthony T. Vella, Jeremy P. McAleer
CD28/B7 Costimulation: A Review
Critical Reviews™ in Immunology, Vol.18, 1998, issue 5
Khuong A. Nguyen, Vijay K. Kuchroo, Edward A. Greenfield